Back to results
US 2022/0031725 A1Published application
Treatment of aging-associated conditions by dna degradation
AssigneeThe General Hospital Corporation
InventorsYuk Yuen Lan, Nir Hacohen
Life of this patent
Estimating the term…
Abstract
Provided herein, in some embodiments, are methods for treating age-associated conditions, including systemic inflammation and disease, via enhanced DNA degradation.
Claims26
A method for treating an aging-associated condition in a subject, comprising:
- increasing expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject.
A method for protecting against an aging-associated condition in a subject, comprising:
- increasing expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject.
A method for treating an aging-associated condition in a subject, comprising:
- identifying a subject as having elevated levels of extranuclear DNA relative to a control;
- and increasing expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject.
A method for treating an aging-associated condition in a subject, comprising:
- identifying a subject as having elevated levels of SA-β-gal activity relative to a control;
- and increasing expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject.
A method for treating an aging-associated condition in a subject, comprising:
- identifying a subject as having elevated levels of:
- (i) one or more autophagy genes, optionally ATG5, BECLIN1, P62, or PTEN;
- (ii) one or more autophagosome marker, optionally LC3;
- (iii) one or more lysosomal protein, optionally LAMP1;
- and/or
- (v) one or more inflammatory genes, optionally MX1, CXCL10, or IL-6 relative to a control;
- and
- increasing expression, bioavailability, and/or bioactivity of a DNase enzyme in the subject.
5 more elements
Dependencies are inferred from the claim text.